Journal article
Thrombolytic-Associated Cholesterol Emboli Syndrome: Case Report and Literature Review
Pharmacotherapy, Vol.15(4), pp.441-450
07/08/1995
DOI: 10.1002/j.1875-9114.1995.tb04380.x
PMID: 7479196
Abstract
Thrombolytics can cause cholesterol embolization syndrome (CES). This adverse effect has received less attention than other risks of thrombolytic therapy, such as systemic bleeding and hemorrhage, with only sporadic reports of CES in the literature. Risk factors have not been consistently identified and emphasized; therefore, occurrence of CES after thrombolysis remains difficult to predict, it results in substantial morbidity and mortality, and it lacks effective pharmacologic treatment. Heightened awareness of the disorder can aid in its correct identification and reporting. 1995 Pharmacotherapy Publications Inc.
Details
- Title: Subtitle
- Thrombolytic-Associated Cholesterol Emboli Syndrome: Case Report and Literature Review
- Creators
- Douglas R. Geraets - University of IowaJames D. Hoehns - University of IowaTimothy G. Burke - Colleges of Pharmacy, University of Iowa, Iowa City, IowaMaleah Grover-McKay - Medicine, University of Iowa, Iowa City, Iowa
- Resource Type
- Journal article
- Publication Details
- Pharmacotherapy, Vol.15(4), pp.441-450
- Publisher
- Blackwell Publishing Ltd
- DOI
- 10.1002/j.1875-9114.1995.tb04380.x
- PMID
- 7479196
- ISSN
- 0277-0008
- eISSN
- 1875-9114
- Number of pages
- 10
- Language
- English
- Date published
- 07/08/1995
- Academic Unit
- Pharmacy Practice and Science
- Record Identifier
- 9984366036702771
Metrics
9 Record Views